Sangamo Therapeutics Inc
NASDAQ:SGMO 3:59:58 PM EDT
Earnings Announcements
Sangamo Therapeutics Reports Recent Business Highlights And Second Quarter 2022 Financial Results
Published: 08/04/2022 20:52 GMT
Sangamo Therapeutics Inc (SGMO) - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results.
Revenues for Q2 Ended June 30, 2022, Were $29.4 Million, Compared to $27.9 Million for Same Period in 2021.
Financial Guidance for 2022 Reiterated.
Revenues for Q2 Ended June 30, 2022, Were $29.4 Million, Compared to $27.9 Million for Same Period in 2021.
Financial Guidance for 2022 Reiterated.
Revenue is expected to be $26.59 Million
Adjusted EPS is expected to be -$0.36
Next Quarter Revenue Guidance is expected to be $26.75 Million
Next Quarter EPS Guidance is expected to be -$0.37
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.36
Next Quarter Revenue Guidance is expected to be $26.75 Million
Next Quarter EPS Guidance is expected to be -$0.37
More details on our Analysts Page.